Board Members 2026-2027

C. Anthony Altar, PhD, Splice Therapeutics

Enrique Carrazana, MD, Neurelis

Gail Farfel, PhD, Board Director, Neurvati/GRIN Therapeutics and the Dravet Syndrome Foundation

Kazuo Fujihara, MD, Fukushima Medical University School of Medicine

Dietrich Haubenberger, MD, Neurocrine Biosciences

Aditya Joshi, MD, University of Pennysylvania

Patrick Malone, kDT Ventures

Richard Ransohoff, Third Rock Ventures

Kenneth Sommerville, MD, Sommerville Consulting

Tom Sutula, MD, PhD, University of Wisconsin Madison

Sharon Tamir, Neurizon Therapeutics

Andrew Cole, MD (Past President), Massachusetts General Hospital, Harvard Medical School

Ludy Shih, MD, MMSc (President), Beth Israel Deaconess Medical Center, Harvard Medical School

Maral Mouradian, MD, Rutgers Robert Wood Johnson Medical School (Editor-In-Chief, ex officio)

Amir Tamiz, PhD, National Institutes of Neurological Disorders and Stroke (ex officio)

Debra Ehrlich, MD, National Institutes of Neurological Disorders and Stroke (ex officio)

Scientific Program Committee Members 2026-2027

Deena Andreola, Takeda Pharmaceuticals

Suhayl Dhib-Jalbut, MD, Rutgers Robert Wood Johnson Medical School

Gail Farfel, PhD, Board Director, Neurvati/GRIN Therapeutics and the Dravet Syndrome Foundation

Marjan Gharagozloo, PhD, Johns Hopkins University

Aditya Joshi, MD, University of Pennysylvania (Chair)

A. Michelle Manzo, MPH, Xenon Pharmaceuticals

Jennifer Morganroth, MD, MBA, Massachusetts General Hospital, Harvard Medical School

Harumasa Nakamura, MD, PhD, National Center of Neurology and Psychiatry, Tokyo, Japan

Yazmin Odia, MD, Louisiana State University (Co-Chair)

Parisa Sanandaji, Stoke Therapeutics

Nancy Santilli, Santilli Global LLC

Sean Savitz, MD, University of Texas Health Science Center at Houston

Ludy Shih, MD, MMSc, Beth Israel Deaconess Medical Center, Harvard Medical School

Carolyn Tallon, PhD, Circumvent Pharmaceuticals

Sharon Tamir, Neurizon Therapeutics

Debra Ehrlich, MD, National Institutes of Neurological Disorders and Stroke (ex officio)

Amir Tamiz, PhD, National Institutes of Neurological Disorders and Stroke (ex officio)